


**REQUEST FOR ACCESS TO AN APPLICATION UNDER 37 CFR 1.14(e)**

In re Application of	
Application Number <i>08/243342</i>	Filed
Art Unit <i>3301</i>	Examiner <i>And</i>

Paper No. *28*

Assistant Commissioner for Patents  
Washington, DC 20231

1. ☐ I hereby request access under 37 CFR 1.14(e)(2) to the application file record of the above-identified ABANDONED Application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and is: (CHECK ONE)

☒ (A) referred to in:

United States Patent Application Publication No. \_\_\_\_\_, page \_\_\_\_\_, line \_\_\_\_\_,

United States Patent Number *6,080,407*, column \_\_\_\_\_, line \_\_\_\_\_, or

an International Application which was filed on or after November 29, 2000 and which

designates the United States, WIPO Pub. No. \_\_\_\_\_, page \_\_\_\_\_, line \_\_\_\_\_.

☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11(b) or

1.14(e)(2)(i), i.e., Application No. \_\_\_\_\_, paper No. \_\_\_\_\_, page \_\_\_\_\_, line \_\_\_\_\_.

2. ☐ I hereby request access under 37 CFR 1.14(e)(1) to an application in which the applicant has filed an authorization to lay open the complete application to the public.

*Samone Sombat*  
Signature

*Samone Sombat*  
Typed or printed name

*1/9/03*  
Date

FOR PTO USE ONLY	
Approved by: _____	(initials)
Unit: _____	

Attn: Henry



US006080407A

## United States Patent [19]

Bucala et al.

[11] Patent Number: 6,080,407

[45] Date of Patent: \*Jun. 27, 2000

## [54] DIAGNOSTIC ASSAYS FOR MIF

[75] Inventors: Richard J. Bucala; Robert A. Mitchell; Jurgen Bernhagen; Thierry F. Colandra, all of New York; Anthony Cerami, Sheller Island, all of N.Y.

[73] Assignee: The Picower Institute for Medical Research, Manhasset, N.Y.

[\*] Notice: This patent is subject to a terminal disclaimer.

[21] Appl. No.: 08/471,586

[22] Filed: Jun. 6, 1995

## Related U.S. Application Data

[60] Division of application No. 08/462,350, Jun. 5, 1995, abandoned, which is a continuation-in-part of application No. 08/243,342, May 16, 1994, abandoned, which is a continuation-in-part of application No. 08/063,398, May 17, 1993, abandoned.

[51] Int. Cl.<sup>7</sup> ..... A61K 39/395

[52] U.S. Cl. .... 424/158.1; 424/145.1; 424/198.1; 530/387.3; 530/388.23; 530/389.2; 514/169

[58] Field of Search ..... 424/184.1, 145.1, 424/130.1, 198.1, 172.1, 158.1, 152.1, 143.1, 141.1, 133.1, 144.1; 530/387.1, 388.24, 388.23, 388.73, 389.2, 387.3; 514/169

## [56] References Cited

## U.S. PATENT DOCUMENTS

4,683,202 7/1987 Mullis.  
5,530,101 6/1996 Queen et al. .... 530/387.3

## FOREIGN PATENT DOCUMENTS

592753 11/1985 Australia ..... C07K 3/12

## OTHER PUBLICATIONS

Nalankon et al., *Annals of Internal Medicine*, vol. 120: 771-783, Jan. 1994.  
Kuby, *Immunology*, W.H. Freeman & Co., New York, pp. 357-358 and 378-379, 1992.  
Taber Cyclopedic Medical Dictionary, F.A. Davis Co., Philadelphia, 14th Edition p. 603, 1984.  
Dorland's Illustrated Medical Dictionary, W.B. Saunders Co., Philadelphia, p. 387 (27th Edition), 1988.  
David et al., "Delayed Hypersensitivity in Vitro: Its Mediation By Cell Free Substances Formed By Lymphoid Cell-Antigen Interaction", *Pathology* 56:72-77 (1966).  
Bennett and Bloom, "Mechanism of a Reaction in Vitro Associated with Delayed-Type Hypersensitivity", *Science* 153:80-82 (1966).  
Nathan et al., "Alterations of Macrophage by Mediators From Lymphocytes", *J Exp Medicine* 133:1356-1376 (1971).  
Nathan et al., "Characterization of a Lymphocyte Factor Which Alters Macrophage Functions", *J Exp Medicine* 137:275-288 (1973).

Kohler and Milstein, "Continuous Culture of Fused Cells Secreting Antibody of Predefined Specificity", *Nature* 256:495-497 (1975).

Weiner et al., "Studies of Human Migration Inhibitory Factor: Characterization of Three Molecular Species", *J Immunol* 126:1958-1962 (1981).

Kaiser and Kezdy, "Secondary Structures of Proteins and Peptides in Amphiphilic Environments (A Review)", *Proc Natl Acad Sci USA* 80:1137-1143 (1983).

Peck, "The Elisa Method for Quantitation of Macrophage Migration from Agarose Macrodrops", *J Immunol Methods* 64:179-187 (1983).

Morrison et al., "Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains", *Proc Natl Acad Sci* 81:6851-6855 (1984).

Sprung et al., "The Effects of High Dose Corticosteroids in Patients with Septic Shock", *New Eng J Med* 311:1137-1143 (1984).

Beutler et al., "Purification of Catechin, A Lipoprotein Lipase-Suppressing Hormone Secreted by Endotoxin-Induced Raw 264.7 Cells", *J Exp Med* 161:984-995 (1985).

Erne et al., "Preferred Conformation, Orientation, and Accumulation of Dynorphin A-(1-13)-Thidecapeptides on the Surfaces of Neutral Lipid Membranes", *Biochemistry* 24:4263-4265 (1985).

Beutler et al., "Catechin/Tumor Necrosis Factor: Production, Distribution, and Metabolic Fate in Vivo", *J Immunol* 135:3972-3977 (1985).

Suzuki et al., "Pituitary-Dependent and -Independent Secretion of CS Caused by Bacterial Endotoxin in Rats", *Am J Physiol* 250:E470-E474 (1986).

Liu and Too A, "Monoclonal Antibody Specific for a Monocyte-Macrophage Membrane Component Blocks the Human Monocyte Response to Migration Inhibitory Factor", *J Immunol* 137:448-455 (1986).

Thomas and Cappocchi, "Site-Directed Mutagen by Gene Targeting in Mouse Embryo-Derived Stem Cells", *Cell* 51:503-512 (1987).

Bone et al., "A Controlled Clinical Trial of High-Dose Methylprednisolone in the Treatment of Severe Sepsis and Septic Shock", *New Eng J Med* 311:1137-1141 (1987).

Ding et al., "Release of Reactive Nitrogen Intermediates and Reactive Oxygen Intermediates From Mouse Peritoneal Macrophages", *J Immunol* 141:2407-2413 (1988).

(List continued on next page.)

Primary Examiner—Christina Y. Chan  
Assistant Examiner—Patrick Nolan  
Attorney, Agent, or Firm—Jeffrey B. Oster

## [57] ABSTRACT

The present invention relates to compositions and methods for inhibiting the release and/or biological activity of migration inhibitory factor (MIF). In particular, the invention relates to the uses of such compositions and methods for the treatment of various conditions involving cytokine-mediated toxicity, which include, but are not limited to shock, inflammation, graft versus host disease, and/or autoimmune diseases.

18 Claims, 22 Drawing Sheets

FW CD +  
hardcopy  
NO refs